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 There is a clinical need for new technologies to measure platelet function in whole 
blood 
 Mild bleeding disorders were evaluated using multiple electrode aggregometry 
(MEA) and lumi-LTA 
 MEA is relatively insensitive at detecting patients with mild platelet function and 
secretion defects 








Background: Multiple electrode aggregometry (MEA) measures changes in electrical 
impedance caused by platelet aggregation in whole blood. This approach is faster, more 
convenient and offers the advantage over light transmission aggregometry (LTA) of 
assessing platelet function in whole blood and reducing pre-analytical errors associated with 
preparation of platelet rich plasma (PRP). Several studies indicate the utility of this method 
in assessing platelet inhibition in individuals taking antiplatelet agents e.g. aspirin and 
clopidogrel.  
Objective: Our current study sought to evaluate the ability of MEA in diagnosing patients 
with mild bleeding disorders by comparison with light transmission lumi-aggregometry 
(Lumi-LTA).  
Methods: 40 healthy subjects and 109 patients with a clinical diagnosis of a mild bleeding 
disorder were recruited into the UK Genotyping and Phenotyping of Platelets study (GAPP, 
ISRCTN 77951167). MEA was performed on whole blood using one or two concentrations of 
ADP, PAR-1 peptide, arachidonic acid and collagen. Lumi-LTA was performed in PRP using 
several concentrations of ADP, adrenaline, arachidonic acid, collagen, PAR-1 peptide and 
ristocetin.  
Results: Of 109 patients tested, 54 (49%) patients gave abnormal responses by lumi-LTA to 
one or more agonists. In contrast, only 16 (15%) patients were shown to have abnormal 
responses to one or more agonists by MEA.  
Conclusions: In this study we showed that MEA is less sensitive in identifying patients with 
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Individuals with inherited platelet function disorders (PFD) comprise a heterogeneous group 
characterised by impaired platelet function and variable bleeding symptoms which in some 
cases can be life threatening. Characterisation of individual platelet function defects is 
crucial for optimal treatment and management as even frequent minor bleeding episodes 
can have a significant impact on quality of life. Diagnosis of severe forms of PFDs such as 
Glanzmann Thrombasthenia (GT) and Bernard-Soulier Syndrome (BSS) is less challenging 
because bleeding symptoms are not only usually identified early in life, but laboratory tests 
are often straightforward due to absence of aggregation and ristocetin induced 
agglutination, respectively [1, 2], and lack of expression of glycoproteins measured by flow 
cytometry [3]. In contrast, diagnosis of the milder forms of PFDs is complex and challenging. 
Bleeding symptoms may not manifest in early age due to absence of haemostatic challenges 
such as surgery, injury, and childbirth. Additionally, many PFDs exhibit unclear penetrance 
and symptoms are similar to other haemostatic disorders including type 1 Von Willebrand 
Disease (VWD) [4]. 
 
A number of tests are currently available to assess platelet function. The most commonly 
used is LTA which was first described by Born over 50 years ago [5].  The test measures the 
change in light transmission in real time when agonists are added to PRP or washed 
platelets. A typical panel of agonists includes ADP, collagen, arachidonic acid, adrenaline, 
PAR-1 peptide, U46619 and ristocetin [6]. The nature of the response is dependent on the 
agonist used, its concentration and the role of the feedback agonists ADP and 
thromboxane A2 (TxA2). During aggregation the platelet response may demonstrate an initial 
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increase in optical density as a result of shape change, followed by a primary, biphasic, 
sustained or reversible increase in light transmission [7]. The secretion of platelet ATP from 
the dense granules can be simultaneously monitored using luminescence by addition of 
luciferin–luciferase reagents.  Measuring the secretion of dense granules is important in 
diagnosis of Hermansky-Pudlak syndrome (HPS) and other dense granule secretory and 
release disorders. However, a defect in ATP secretion cannot discriminate between 
abnormal granule formation or defects in platelet signaling, necessitating additional 
investigations such as  electron microscopy, serotonin uptake and measurement of total 
platelet ATP/ADP content [4]. Although LTA is considered to be the gold standard method 
for the investigation of platelet function, the technique is time consuming, requires large 
blood volumes for preparation of PRP, needs to be performed on fresh samples and requires 
expertise for correct performance and interpretation [8]. Moreover, not all laboratories use 
lumi-LTA as a recent worldwide survey showed that 40.7% of laboratories use this for the 
diagnosis of inherited platelet function defects [9].   
 MEA has recently been developed for rapid assessment of platelet function. The device 
evaluates platelet responses in disposable ready-to-use test cuvettes, each containing two 
pairs of electrodes enabling two simultaneous measurements. During the test activated 
platelets adhere onto the sensor wires resulting in increased electrical resistance which is 
continuously monitored and reported as the area under the curve (AUC). As a whole blood 
method, MEA only requires small blood volumes making it possible to be used as a point of 
care test with standardized reagents. In addition, the use of whole blood offers the 
advantage of assessing platelet function under more physiological conditions and avoids the 
variables associated with the preparation of PRP [10]. Although MEA can also measure the 
7 
 
kinetic changes in aggregation over time including the parameters of lag time, slope and 
area under the curve and maximal aggregation, the traces are not as detailed as LTA which 
not only measures these but also includes shape change, primary (reversible) and secondary 
aggregation responses.  In addition, MEA does not measure released ATP in parallel with 
aggregation.  As MEA is becoming increasingly popular for measuring antiplatelet therapy 
and has been shown to be useful for detecting severe PFDs we assessed the potential utility 
of MEA for detecting mild PFDs by comparison with the current gold standard, lumi-LTA in 
participants recruited to the GAPP Study [11].  
Materials and Methods 
Participants 
Between September 2013 and November 2015, a total of 149 individuals (109 patients and 
40 controls) were evaluated and recruited into the GAPP study 
(www.birmingham.ac.uk/plateletgapp) from 9 UK Haemophilia Care Centres. All patients or 
their parents gave written informed consent in accordance with the GAPP project ethical 
approval (REC reference: 06/MRE07/36).    
Reagents  
ADP, ristocetin and adrenaline were purchased from Sigma (Poole, UK). Arachidonic acid 
and U46619 were purchased from Cayman Chemical Company (Michigan, USA). The PAR1 
peptide (SFLLRN) was purchased from Severn Biotech (Kidderminster, UK). Collagen was 
purchased from Takeda (Austria) and luciferin luciferase reagent (Chrono-lume) was 
purchased from Chrono-log Corporation (Havertown, PA, USA). The reagents were dissolved 
in phosphate-buffered saline (PBS) at pH 7.4 and stored as frozen aliquots, thawed and 
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diluted in PBS when required and kept on ice. Collagen was stored as a concentrated stock 
at 1 mg/ml as supplied by the manufacturer at 4°C and diluted with the buffer provided. 
Blood Sampling 
Whole blood (40 ml from adults and 20 ml from children) was obtained and anticoagulated 
with one tenth volume of 0.109 mol/L buffered trisodium citrate in vacutainer plastic tubes 
(Becton Dickinson, Plymouth, UK). An additional 2-3 ml blood was anticoagulated with EDTA 
in vacutainer plastic tubes (Becton Dickinson, Plymouth, UK). The same volume of blood was 
collected from a healthy control at the same time in each Centre. Blood samples were 
immediately transported to the testing laboratory and assayed within 4 hours (by MEA) and 
within 6 hours (by lumi-LTA) from collection. 
Blood sample preparation  
PRP was prepared by centrifuging the citrated blood samples at 200 g for 20 min. PRP was 
transferred carefully into a 15 ml Falcon tube, capped and stored upright at room 
temperature. Platelet-poor plasma (PPP) was prepared by further centrifugation at 1,000 g 
for 10 min and transferred into a 15 ml Falcon tube, capped and stored upright at room 
temperature. About 2-3 ml of the buffy coat layer was also taken from the same tubes and 
stored at -80oC for DNA analysis.  
Whole blood platelet counting using the Sysmex XN-1000 analyser 
EDTA blood samples from patients and controls were analysed using the XN-1000 whole 
blood counter (Sysmex UK, Milton Keynes). The XN-1000 is a state of the art whole blood 
analyser that is capable of rapidly producing a full blood differential cell count from 88µl of 
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human blood. The analyser has a set of unique platelet parameters including three platelet 
counts: platelet impedance (PLT-I), platelet optical (PLT-O) and platelet fluorescence (PLT-F) 
count, platelet mean volume (MPV) and the immature platelet fraction (IPF). Platelet 
counts, MPV and IPF were recorded for each patient and compared against reference 
ranges established from 40 healthy normal controls. Quality assurance of the instrument 
was checked by an internal quality control using commercial fixed samples (Xn check, 
Sysmex UK, Milton Keynes) with known cell counts and testing samples provided by an 
external quality assessment scheme (UKNEQAS, Watford, UK). 
Platelet counting of PRP 
An impedance analyser (Coulter Z2 Beckman Coulter, High Wycombe, Bucks, UK) was used 
to count the platelets within the PRP by diluting 5 µl of PRP into 10 ml of fresh Isoton II 
diluent (Beckman Coulter, Bucks, UK). The platelets were counted in triplicate and the mean 
was calculated and recorded.  
Platelet aggregation in whole blood  
Whole blood impedance aggregometry was performed on citrated blood using MEA (Roche 
Diagnostics, Munich, Germany) consisting of 5 reaction channels, an integrated computer, 
and guided automatic pipetting. The tests were performed in disposable ready-to-use test 
cells with 2 independent sensor units consisting of 2 silver-coated highly conductive copper 
electrodes (Roche Diagnostics, Munich, Germany). In each test cuvette, mixed whole 
citrated blood (300 μl) was immediately diluted, 1:1 vol/vol, with 0.9% saline solution and 
incubated at 37°C for 3 min before addition of 30 μl of each agonist. Platelets were 
stimulated with a range of agonists including ADP (10 and 2.5 µM), PAR-1 peptide (100 µM), 
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collagen (1 and 3 µg/mL) and arachidonic acid (0.5 mM).  During the test, platelets adhere 
and aggregate upon the sensor electrode surfaces resulting in an increase in the electrical 
resistance (impedance) and the signal recorded and plotted as aggregometer trace. The 
total aggregation measured with this device is quantified as AUC or AU*min. 
Platelet aggregation in platelet-rich plasma 
Tests were carried out as described previously [7].  Aggregation studies were performed by 
using a dual Chrono-log lumiaggregometer (model ChronoLog 460 VS aggregometer, 
LabMedics, UK) in 400 μL mini cuvettes and stirred at 1200 rpm at 37°C. The 100% line was 
set using autologous platelet-poor plasma (PPP) and the 0% baseline established with native 
undiluted PRP.   After one min platelets were stimulated with ADP (10, 30, and 100 µM), 
adrenaline (10, 30, and 100 µM), arachidonic acid (0.5, 1, and 1.5 mM), U46619 (1 and 3 
M), collagen (1 and 3 µg/mL), CRP (1, 3, and 10 µg/mL), PAR-1 peptide (10, 30 and 100 
µM), and ristocetin (1.5 and 2 mg/mL).  Platelet aggregation was monitored by measuring 
the change in optical density over 5 min after addition of the agonists and the maximal 
percentage of aggregation was recorded.  
ATP secretion 
ATP secretion from platelet dense granules was assessed simultaneously by lumi-LTA using 
the luciferase reagent (Chronolume). 30 µl of Luciferin reagent was added to the PRP and 
incubated for 1 minute. Platelets were then stimulated with the agonists listed above and 
monitored for 5 min followed by addition of 4 µl of an ATP standard (2 µM final 
concentration) to facilitate internal calibration. Secreted ATP levels were calculated by 
measuring the maximal amplitude of luminescence during the aggregation to a high dose of 
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PAR-1 peptide (100 M) and comparing to the standard. A low cut-off point of 0.65 nmol 
ATP / 108 platelets was established from previously studied healthy volunteers. 
Statistical analysis  
All control results were run on IBM SPSS Statistics version 20 and Graph Pad Prism version 
7.0 software to demonstrate the normal distribution and to obtain the mean and standard 
deviation values which were then used to determine the cut-off values.  Abnormal results by 
Lumi-LTA were determined based on our previously published methodology that is based 
upon both the magnitude and time course of response [7, 11].  The time course, including 
reversibility is of particular importance. In contrast, because of the lack of these detailed 
kinetic changes detected by MEA, abnormal results were determined based on the cut off 
values calculated as the 5th percentile of responses of normals to ADP 10 µM, collagen 1 
µg/ml, collagen 3 µg/ml, PAR1 100 µM and arachidonic acid 0.5mM were 19.1, 21, 35.1, 
42.3 and 19.7 (AUC), respectively 
Results 
Overall comparison between MEA and Lumi-LTA 
We analysed a total of 109 patients (21 male and 88 female) with a median age 33 (range 3-
73) and 40 healthy adult volunteers (18 - 57) recruited into the GAPP study and compared 
MEA results with lumi-LTA. The overall haematological parameters and ATP secretion value 
of patients and healthy individuals are shown in Table 1. Of 109 patients tested (Table 2), 54 
(49%) patients gave abnormal responses by lumi-LTA to one or more agonists as defined 
using previous criteria [11]. In contrast, only 16 (15%) patients were shown to have 
abnormal responses to one or more agonists by MEA, as defined using the cut off values 
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obtained from healthy individuals. The overall agreement between the two instruments is 
shown in Table 3. 65/109 samples gave identical results by both tests, with the majority (52) 
giving normal responses. In contrast, there was disagreement in 44/109 samples. MEA 
detected an abnormality in 3 patients that were normal by lumi-LTA. However, 41 samples 
were normal by MEA but abnormal by lumi-LTA (figure 1).  In 12 (11%) patients with mild 
thrombocytopenia as characterized by low platelet count (<150 x109/L) in whole blood 
(Table 2), abnormal aggregation responses were detected by lumi-LTA on 8 patients and by 
MEA on 6 patients.  In 20 patients with secretion defects characterized by reduced ATP 
levels (Table 2), the lumi-LTA and MEA aggregation responses were abnormal in only 8 and 3 
patients respectively. MEA is therefore less sensitive than lumi-LTA at detecting secretion 
defects which is not surprising in that MEA does not provide a direct readout of secretion. 
 
Correlation between platelet counts and aggregation results by MEA and lumi-LTA   
With MEA we found a significant but weak correlation between whole blood platelet 
counts and aggregation results in response to ADP 10μM (r=0.14, p= 0.016) but not with 
collagen 3 µg/ml (r= 0.072 p= 0.09), PAR-1 100µM (r= 0.043 p= 0.19) and arachidonic acid 
(r= 0.15 p= 0.096) (Supplementary figure 1).  In contrast, with lumi-LTA, a weak correlation 
between the PRP counts and aggregation was only found in response to collagen 3μg/ml (r= 
0.13 p= 0.02) but not with ADP 10μM (r=0.025, p= 0.33), PAR-1 100 (r= 0.026 p= 0.32) and 
arachidonic acid 0.5mM(r= 0.092 p= 0.22 (Supplementary figure 2).  
 
 
Analysis and identification of patients with various platelet function defects 
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Functional defects identified by lumi-LTA were classified into 4 main groups (Gi defect, 
secretion defects, COX-like defect and unclassified defects) according to their pattern of 
responses to specific agonists as previously described [11]. As shown in figure 2, MEA only 
detected 4 out of 17 patients with Gi defects and 2 out of 20 with secretion defects.  MEA 
only detected 4/7 patients with a COX-like defect and none/4 patients with unclassified 
defects by lumi-LTA. Finally MEA gave abnormal responses to 3 samples out of 6 with 
multiple platelet defects. 
 
Correlation between MEA and lumi-LTA with identical concentrations of agonists  
To give a fairer comparison of the two tests, identical concentrations of the agonists ADP, 
collagen and PAR1  peptide were compared by both tests (with no ATP measurements 
included) and confirmed that MEA was still unable to detect some abnormalities detected 
by lumi-LTA 16 (15%) versus 41 (38%). Overall kappa statistics demonstrated only a fair 
agreement between MEA and lumi-LTA in response to ADP (k = 0.26, CI = 0.11 to 0.40) and 
collagen (k = 0.28, CI = 0.05 to 0.52) and a poor agreement in response to PAR1 ( k = 0.07, Cl 
= -0.17 to 0.32) (Figure 3).  
Discussion 
MEA performs platelet aggregation in whole blood and offers the advantage of assessing 
platelet function with more physiological conditions in small blood volumes and without 
sample processing [10]. As MEA is popular for measuring antiplatelet therapy and has been 
shown to be useful for detecting severe PFDs, we assessed the potential utility of MEA for 
detecting mild PFDs [12-15]. 
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Comparison of the overall results in 109 patients with mild PFDs (Table 3) showed a 
moderate agreement between MEA and lumi-LTA with the diagnosis being concordant in 
60% of cases. The underlying genetic causes of these cases are yet to be confirmed by 
sequencing.  Although MEA therefore gave a negative predictive value of 56%, in healthy 
individuals there was good agreement between MEA and lumi-LTA with no difference in 
response between identical concentrations of the agonists ADP, collagen and PAR-1 peptide 
(Figure 3). Our findings support a recent study by Seyfert et al., demonstrating equivalent  
results of MEA and lumi-LTA in healthy samples [16]. In patients’ samples however, we 
observed significant differences between the two techniques with a fair to poor agreement 
between MEA and lumi-LTA with different agonists when overall results were analysed using 
kappa statistics. 
As MEA dilutes the whole blood 1:1 with saline before testing we also investigated the 
influence of platelet counts (within normal ranges) on both MEA and lumi-LTA results. With 
MEA a linear increase in aggregation responses with higher counts was only observed with 
ADP but not collagen, PAR-1 or arachidonic acid. In contrast with lumi-LTA this was only 
observed with collagen but not ADP, PAR-1 or arachidonic acid (See supplementary figures). 
Previous studies with lumi-LTA have found no correlation between platelet count and 
aggregation results [7, 16-18]. Seyfert et al. also found a significant correlation between 
platelet count and platelet aggregation using MEA induced by ADP and collagen, but not by 
arachidonic acid [16]. Mengistu et al. and Stissing et al. also demonstrated the influence of 
platelet count on whole blood aggregometry towards low platelet concentrations [19, 20]. 
Two more studies also reported correlations between platelet count and extent of platelet 
aggregation on MEA [18, 21]. However, the latter results are difficult to interpret as the 
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counts were adjusted either by addition of PPP [21] which is known to inhibit platelet 
aggregation [17], or with dilution with Tyrode's buffer [18].   
We found that MEA also detected more patients classified with COX-1 like defects than 
those with Gi and secretion defects. This suggests that MEA may be more sensitive in 
response to defects in the thromboxane pathway. However, the lack of sensitivity of MEA in 
detecting Gi defects may also be related  to the higher ADP concentration (10 µM) used in 
this study which is slightly higher than the standard recommended concentration  (6.5 µM). 
Interestingly, we have also observed that MEA showed high consistency in detecting 
abnormalities in patients with dual defects. This findings support the earlier reports suggest 
that MEA is reliable in detecting more severe forms of platelet defects such as GT [12, 13].  
Measurement of secreted ATP levels is an additional but important tool in identifying 
patients with platelet secretion defects [22]. Indeed the Chronolog whole blood 
aggregometer can also be used in conjunction with ATP secretion [23]. Moreover, it is well 
known that individuals with reduced dense granule secretion can often demonstrate normal 
aggregation responses [11]. In this study MEA and lumi-LTA gave normal responses on 
17(85%) and 12(60%) patients respectively that were found to have low secreted ATP levels. 
This is probably unsurprising given that MEA does not directly measure ATP secretion and 
the aggregation responses are probably less sensitive at detecting the feedback loop from 
released ATP/ADP from the dense granules.  
Hirudin is the anticoagulant of choice for MEA recommended by the manufacturer [10]. 
Previous studies have shown that different anticoagulants can affect platelet function 
activity [24]. In this study we only used citrated blood for both techniques in order to have a 
similar comparison with identical levels of free calcium levels. Furthermore, a study using 
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citrated blood from healthy individuals showed no significant difference between MEA and 
LTA even at higher citrate concentrations [16]. Storage time between blood collection and 
sample processing is a crucial factor when testing platelet activity particularly on whole 
blood aggregometry. To avoid variation of results due to time delays, MEA was always 
tested during PRP/PPP preparation for LTA to ensure that the analysis was always 
completed rapidly within 4 hours [16, 25].  
Study limitations 
Our study was performed using only trisodium citrate anticoagulant in blood samples tested 
by LTA and MEA. The study was also performed on individuals with suspected mild platelet 
defects with a bleeding history. It would be of interest to fully investigate the utility of MEA 
in patients with a defined set of pre-diagnosed platelet function disorders. ADP was also 
used at a higher concentration of 10 µM above the recommende  
for MEA and may have contributed to the lack of sensitivity observed. 
 
Conclusions 
Overall, MEA demonstrates a lack of sensitivity in identifying patients with mild bleeding 
associated with abnormal platelet function and platelet secretion defects. More studies are 
required to further evaluate the role for MEA in the diagnosis of bleeding disorders.  
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Table 1 Baseline characteristics of healthy individuals (n=40) and patients (n=109).   
 
Data are presented as absolute numbers (percentages) or means (standard deviations) 
 
Table 2 Comparison between MEA and lumi-LTA on overall results, patients with 
thrombocytopenia and patients with reduced ATP levels   
 
 
Table 3 Contingency table showing the overall agreement between the MEA and lumi-LTA in 






Figure 1 Platelet function assessed by MEA (AUC) and lumi-LTA (%) in samples from healthy 
subjects (n=40) and patients (n=109) after stimulation with, ADP 10 μM,  Collagen 3 µg/ml,  
PAR-1 peptide 100 µM and Arachidonic Acid 0.5 mM (healthy subjects= 19 and patients 
=36). The horizontal black lines indicate cut-offs determined as 5th percentile of the 
corresponding measurement in healthy volunteers. In the patient groups: closed circles 
indicate individuals with an abnormality detected by lumi-LTA, and closed squares indicate 
an abnormality detected by MEA.   
 
Figure 2 Bar charts show the number of patients with various platelet function defects 
detected by lumi-LTA (black) and MEA (grey) The response to each agonist was considered 
to be abnormal (on MEA) when it falls below the cut off value that was set from healthy 
individuals and (on lumi-LTA) as defined using previously published criteria [11]. 
 
Figure 3 Correlation between MEA (AUC) and lumi-LTA (%) in samples from healthy subjects 
(n=40, open circles) and patients (n=109, closed circles) after stimulation with, ADP 10μM, 
Collagen 3µg/ml and PAR-1 peptide 100. The vertical black lines indicate the cut-offs value 
of MEA determined as 5th percentile of the corresponding measurement in healthy subjects. 
The horizontal black lines indicate cut-offs value of lumi-LTA previously established in the 
























Supplementary figures   
 
 
Supplementary figure 1 Correlation between  MEA (AUC) and whole blood platelet count 
(x109/L) in samples from healthy subjects (n=40) after stimulation with ADP 10μM, Collagen 







Supplementary figure 2 Correlation between  Lumi-LTA (aggregation %) and PRP count 
(x108/L) in samples from healthy subjects (n=40) after stimulation with ADP 10μM, Collagen 
3µg/ml,  Collagen 1µg/ml, PAR-1 activating peptide 100µM and Arachidonic Acid 0.5mM. 
 
 
